TVG 402 and TVG 403 were the first antibodies against HPV16 E1 & E4 and should complement those already available to E7 and L1 for the screening of frozen sections of clinical biopsies. They will be of value in monitoring the progress of HPV infection from benign lesions to invasive cancer.
| Institute |
|---|
| University of Cambridge |
| Cat. #: | 151171 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Cervical cancer |
| Research Fields: | Cancer;Microbiology |
| Application: | ELISA ; IHC ; IP ; WB |
| Target: | Human Papilloma Virus 16 early proteins 1 and 4 (HPV16 E1/E4) |
| Reactivity: | Human papilloma virus |
| Clone: | TVG 402 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | TVG 402 and TVG 403 were the first antibodies against HPV16 E1 & E4 and should complement those already available to E7 and L1 for the screening of frozen sections of clinical biopsies. They will be of value in monitoring the progress of HPV infection from benign lesions to invasive cancer. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 10 kDa |
| Immunogen: | Antigen for hybridoma production was expressed as a b galactosidase fusion protein using the pEX expression system and was consequently cleaved to release the E1/E4 polypeptide. |
| Myeloma used: | NS0 |
| Target background: | The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer case. E1 and E2 are proteins involved in the regulation of viral DNA replication. TVG 402 and TVG 403 were the first antibodies against HPV16 E1 & E4 and should complement those already available to E7 and L1 for the screening of frozen sections of clinical biopsies. They will be of value in monitoring the progress of HPV infection from benign lesions to invasive cancer. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | '-15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Doorbar et al. 2000. J Virol. 74(21):10081-95. PMID: 11024137. Doorbar et al. 1992. Virology. 187(1):353-9. PMID: 1371027. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.